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role of microbiota-host interactions in
hitherto seemingly unrelated physiolog-
ical processes such as intestinal circadian
clocks and systemic metabolism.
This study leaves us with several
intriguing questions. First, which innate
immune receptors are responsible for
the regulation of the circadian clocks in
IECs? Several TLRs and other receptors
are expressed phasically, but deficiency
in the major essential adaptor for most
TLRs, MyD88, does not cause a similar
phenotype. Some TLRs, such as TLR3
and TLR4, could still signal through the
adaptor TRIF or alternative pathways
that do not require MyD88, such as
RIG-I-like receptors. A second question
is whether different types of intestinal
epithelial cells such as enterocytes,
goblet cells, paneth cells, and stem cells
differ in their regulation of the circadian
clock. An intriguing possibility would be
that one of these populations, for instance
the paneth cells, could serve as pacemakers, affecting other cellular subsets.
Moreover, in light of the large body of
recent work by groups including our
own, which link specific members of
the intestinal microbiota with metabolic
disease (Henao-Mejia et al., 2012; Turn-
baugh et al., 2006; Vijay-Kumar et al.,
2010), these findings raise the exciting
question of whether specific members
of the microbiota have exquisite abilities
to influence the circadian rhythm and
glucocorticoid synthesis. Finally, future
research should decipher the particular
importance of corticosterone produc-
tion in the ileum and the relevance of
the severe metabolic alterations associ-
ated with the disruption of this control
mechanism for both local and systemic
pathologies.REFERENCES
Asfeldt, V.H. (1971). Scand. J. Clin. Lab. Invest. 28,
61–70.CelHenao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal,
W.Z., Strowig, T., Thaiss, C.A., Kau, A.L., Eisen-
barth, S.C., Jurczak, M.J., et al. (2012). Nature
482, 179–185.
Kino, T. (2012). Sci. Signal. 5, pt4.
Lozupone, C.A., Stombaugh, J.I., Gordon, J.I.,
Jansson, J.K., and Knight, R. (2012). Nature 489,
220–230.
Mukherji, A., Kobiita, A., Ye, T., and Chambon, P.
(2013). Cell 153, this issue, 812–827.
Silver, A.C., Arjona, A., Walker, W.E., and Fikrig, E.
(2012). Immunity 36, 251–261.
Tremaroli, V., and Ba¨ckhed, F. (2012). Nature 489,
242–249.
Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Ma-
grini, V., Mardis, E.R., and Gordon, J.I. (2006). Na-
ture 444, 1027–1031.
Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A.,
Cullender, T.C., Mwangi, S., Srinivasan, S., Sitara-
man, S.V., Knight, R., Ley, R.E., and Gewirtz, A.T.
(2010). Science 328, 228–231.Young at Heart
Leslie A. Leinwand1,* and Brooke C. Harrison1
1Department of Molecular, Cellular, and Developmental Biology and BioFrontiers Institute, University of Colorado at Boulder, Boulder,
CO 80309, USA
*Correspondence: leslie.leinwand@colorado.edu
http://dx.doi.org/10.1016/j.cell.2013.04.038
In this issue of Cell, Loffredo et al. demonstrate that exposing an old mouse to the circulatory
system of a young mouse reverses age-related cardiac hypertrophy. The authors demonstrate
that this effect can be recapitulated by treating old mice with growth and differentiation factor 11
(GDF11). These data suggest that GDF11 therapy may be a useful tool in combating age-related
cardiac hypertrophy.Within the context of an increasingly aged
population, the healthcare costs associ-
ated with aging-related heart failure
represent a significant healthcare burden.
Diastolic heart failure, characterized by
impaired cardiac filling during relaxation,
in particular, is a condition lacking specific
and effective therapies (Hunt et al., 2009;
Kitzman and Daniel, 2007). Though
perhaps controversial, there appears to
be an association between an age-relatedincrease in cardiac mass (i.e., cardiac
hypertrophy) and the development of dia-
stolic dysfunction (Dai and Rabinovitch,
2009; Lakatta and Levy, 2003). Age-
related cardiac hypertrophy has been
described in humans and animal models,
but the physiological, hormonal, cellular,
and molecular causes remain poorly
understood. Here, Loffredo et al. demon-
strate that exposing an old mouse to the
circulation of a young mouse using apowerful technique called parabiosis can
reverse many of the biological conse-
quences of age-related cardiac hypertro-
phy (Loffredo et al., 2013). The authors go
on to establish that this effect appears to
be at least partially modulated by a circu-
lating protein called growth and differenti-
ation factor 11 (GDF11).
The traditional technique of parabiosis
involves joining the vasculature of two
animals such that the two animalsl 153, May 9, 2013 ª2013 Elsevier Inc. 743
Figure 1. Systemic GDF11 Reduces Age-Related Cardiac Hypertrophy
(Inset) Heterochronic parabiosis reverses age-related cardiac hypertrophy in mice. Old (O) mice display
increased cardiacmass and cardiomyocyte cross-sectional area compared to young (Y)mice. Heart mass
and myocyte cross-sectional area are reduced in old mice subjected to heterochronic parabiosis with
young mice (YO). Circulating levels of GDF11, possibly from the spleen and other tissues, are reduced in
oldmice. Supplementing oldmicewith recombinant GDF11 reverses age-related cardiac hypertrophy and
promotes beneficial patterns of gene expression. The effects of circulating GDF11 (and associated age-
related changes) on pancreatic insulin production, skeletal muscle, adipose tissue, and other tissues are
unknown.effectively share the same circulatory sys-
tem (Finerty, 1952). With heterochronic
parabiosis, an older animal is exposed to
the circulation of a younger animal. Here,
Loffredo et al. show that 4 months of
heterochronic parabiosis reduces cardiac
mass and cardiomyocyte cross-sectional
area in old mice and promotes a favorable
shift in gene expression, including
reduced natriuretic factor expression
and increased SERCA-2 calcium ATPase
expression. The authors demonstrate
that these changes are not due to alter-
ations in blood pressure or any behavioral
changes due to the physical constraints
of the parabiosis itself. Importantly, the
authors also show that these changes in
cardiac mass do not appear to be due to
alterations in body mass. In fact, while
old heterochronic parabiosis animals do
experience a dramatic reduction in
body mass (32%), this loss is not sig-
nificantly different from that seen in old
animals from a sham heterochronic
parabiosis experiment (25%). Given
the importance of body mass in dicta-
ting the overall metabolic demand and
thus cardiac workload, it is certainly
important to consider alterations in
body mass in these types of parabiotic
experiments.744 Cell 153, May 9, 2013 ª2013 Elsevier IncHaving established that exposure to a
young circulation effectively remodels
the aged heart, Loffredo et al. utilize
aptamer-based technology to identify
GDF11 as one of the circulating factors
that is significantly different between
young and old mice. A member of the
activin/TGFb superfamily of growth and
differentiation factors, GDF11, binds the
activin-type IIB receptor (ActRIIB) and
promotes activation of the Smad 2/3
pathway (McPherron et al., 1999). Within
the TGFb superfamily, GDF11 is most
similar to myostatin (mstn or GDF8), a
well-known negative regulator of skeletal
muscle mass (McPherron et al., 1997).
However, though there appears to be
some functional redundancy between
myostatin and GDF11, the overall biolog-
ical functions of GDF11 are relatively
poorly understood (McPherron et al.,
1997, 1999). Though myostatin null mice
are viable and display a dramatic increase
in skeletal muscle mass combined with
reduced adiposity, GDF11 null mice die
within 24 hr of birth, with severe skeletal
and renal abnormalities (McPherron,
2010; McPherron et al., 1999, 2009). In
fact, analysis of GDF11 null mice reveals
alterations in Hox gene expression and
indicates a role for GDF11 in patterning.positional identity along the anterior/
posterior axis (McPherron et al., 1999).
Follow-up validation experiments by
Loffredo et al. confirmed that GDF11 is
widely expressed in mouse tissues, with
highest levels of mRNA expression in the
spleen. Importantly, the authors demon-
strate that splenic GDF11 mRNA expres-
sion and protein levels decline with aging
in the mouse, as do circulating levels.
The authors then show that treatment of
neonatal rat cardiomyocytes with re-
combinant GDF11 (rGDF11) inhibits
cellular hypertrophy in the presence of
the prohypertrophic stimulus, phenyleph-
rine. Furthermore, treatment of human-
induced pluripotent stem-cell-derived
cardiomyocytes with rGDF11 activates
the TGFb pathway and suppresses
FOXO phosphorylation. With these
in vitro data in hand, the authors supple-
mented old mice with rGDF11 to restore
‘‘youthful’’ levels of the signaling factor.
In fact, old mice given rGDF11 for
30 days demonstrate a similar cardiac
phenotype as the old mice from the heter-
ochronic parabiotic pair experiments,
with reduced cardiac mass, smaller
cardiomyocytes, and favorable changes
in gene expression. Interestingly, the
authors show that daily rGDF11 supple-
mentation does not impact cardiac
hypertrophy due to aortic constriction,
indicating that the cardiac effects of
GDF11 with respect to cardiac hyper-
trophy appear to be etiology specific.
These findings raise several questions
for future research. Considering that the
‘‘aged’’ phenotype often includes re-
duced skeletal muscle mass, increased
adiposity, and reduced insulin sensitivity,
it will be interesting to see whether circu-
lating GDF11 impacts these body sys-
tems in addition to the heart (Figure 1).
Though skeletal-muscle-derived GDF11
does not appear to regulate skeletal
muscle fiber size and composition, the
effects of systemic circulating GDF11 on
skeletal muscle are poorly understood
(McPherron et al., 2009). Based on the
data of Loffredo et al., it is intriguing to
speculate that the age-related decline in
circulating GDF11 may also impact
skeletal muscle mass and function. Like-
wise, the effects of circulating GDF11 on
adiposity and fat metabolism are un-
known. However, given that mice lacking
myostatin have increased muscle mass
and reduced adiposity, it might be pre-
dicted that an age-related decline in
GDF11 could produce similar (albeit
smaller) effects. Similarly, there are con-
flicting data, suggesting that GDF11
may or may not be involved in the mainte-
nance of pancreatic b-cell function (Dich-
mann et al., 2006; Harmon et al., 2004).
Together, these data and those of
Loffredo et al. indicate that age-related
alterations in circulating GDF11 levels
may also impact glucose/insulin homeo-
stasis. Overall, these questions suggest
that further study of GDF11 and its rela-
tive contributions with respect to
the system-wide aged phenotype are
worthwhile.
In summary, the work of Loffredo et al.
identifies GDF11 as a modulator of
age-related cardiac hypertrophy. These
findings suggest that GDF11 supplemen-
tation in older individuals may represent a
new tool for targeting age-related cardiac
hypertrophy and thus possibly provide anew approach for the treatment of age-
related diastolic dysfunction. If GDF11
supplementation is to be considered as
a possible therapy, further experimenta-
tion is required to elucidate the effects of
GDF11 on other body systems, including
skeletal muscle, adipose tissue, and
pancreatic insulin production.ACKNOWLEDGMENTS
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